Clinical Trial Update: Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial to prevent ototoxicity in patients with nontuberculous mycobacterial infection treated with IV amikacin; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nontuberculous Mycobacterial Infection

Drugs mentioned

• Amikacin (amikacin)

Snippet

Sponsor: Kevin Winthrop | Conditions: Ototoxicity, Drug-Induced | Phase 2 | Status: RECRUITING